EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Future of Continuous Ketone Monitoring and Its Utility for Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in Type 1 Diabetes

Halis K Akturk

Endocrinology and Metabolism Clinics of North America · 2026-09 · 55 (3) · 515-524

DOI: 10.1016/j.ecl.2026.04.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Endocrinology and Metabolism Clinics of North America, 2026-09. Verfasst von Halis K Akturk. Beteiligte Einrichtung: Barbara Davis Center for Diabetes, School of Medicine, University of Colorado Anschutz Campus, Aurora, CO, USA. Electronic address: Halis.akturk@cuan…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Sodium-Glucose Transporter 2 Inhibitors, Diabetic Ketoacidosis, Ketones. Die Arbeit nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Continuous ketone monitoring (CKM) may address the principal barrier to adjunctive sodium-glucose cotransporter-2 inhibitor use in type 1 diabetes: Unrecognized ketosis and euglycemic diabetic ketoacidosis. Unlike conventional urine or capillary ketone testing, CKM provides real-time β-hydroxybutyrate trends and may identify rising ketones before clinical symptoms. Emerging dual glucose-ketone sensors could improve risk stratification, support earlier intervention, refine ketone mitigation protocols, and potentially integrate with automated insulin delivery systems. Although promising, CKM remains an emerging technology. Studies are needed to define actionable thresholds, validate outcomes, and determine whether it can safely expand the use of adjunctive therapies in type 1 diabetes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Sodium-Glucose Transporter 2 InhibitorsDiabetic KetoacidosisKetonesHypoglycemic AgentsHumans

Stichwörter der Autor:innen

Beta hydroxybutyrateContinuous ketone monitoringDiabetic ketoacidosisSGLT2 inhibitorsType 1 diabetes

Substanzen

Sodium-Glucose Transporter 2 InhibitorsKetonesHypoglycemic Agents

Autor:innen und Institutionen

  • Barbara Davis Center for Diabetes, School of Medicine, University of Colorado Anschutz Campus, Aurora, CO, USA. Electronic address: Halis.akturk@cuanschutz.edu.

Zitieren

APA

Akturk, H. K. (2026). Future of Continuous Ketone Monitoring and Its Utility for Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America, 55(3), 515-524. https://doi.org/10.1016/j.ecl.2026.04.005

Vancouver

Akturk HK. Future of Continuous Ketone Monitoring and Its Utility for Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in Type 1 Diabetes. Endocrinology and Metabolism Clinics of North America. 2026;55(3):515-524. doi:10.1016/j.ecl.2026.04.005

BibTeX
@article{Akturk2026,
  author = {Akturk, Halis K},
  title = {Future of Continuous Ketone Monitoring and Its Utility for Safe Use of Sodium-glucose Cotransporter-2 Inhibitors in Type 1 Diabetes},
  journal = {Endocrinology and Metabolism Clinics of North America},
  year = {2026},
  volume = {55},
  number = {3},
  pages = {515--524},
  doi = {10.1016/j.ecl.2026.04.005}
}
Kostenlos starten →